Breast Cancer
From the Journals
Higher risk of death with endocrine therapy nonadherence
“Importantly, improving adherence and persistence represents a low-hanging fruit for increasing survival in luminal breast cancer.”
From the Journals
PET-CT scans move more women with LABC up to stage IV
The results of a new study comparing the use of PET-CT with conventional methods for staging locally advanced breast cancer has already changed...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
From the Journals
Breast cancer family history linked to better BC survival
A family history of breast cancer was associated with a lower risk of breast cancer-specific death, after adjustments, a new study finds.
Latest News
T-DXd active in many solid tumors; ‘shift in thinking’
T-DXd is a potential new treatment option for patients with HER2-expressing solid tumors, experts say.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
‘Professional grief’ is a daily reality for oncologists
“We could make the work easier to do so that you have more time with patients and less time with administrative work and have more time to process...
Commentary
ASCO 2023: Promising results in breast cancer from NATALEE and PHERGain
This is what we’ve been waiting for. Can we identify those patients who have an excellent prognosis with biologic therapy alone so that we can...